Fatal insomnia is an extremely rare genetic (and even more rarely, sporadic) disorder that results in trouble sleeping as its hallmark symptom. The problems with sleeping typically start out gradually and worsen over time. Eventually, the patient will succumb to total insomnia (agrypnia excitata), most often leading to other symptoms such as speech problems, coordination problems, and dementia. It results in death within a few months to a few years and has no known cure.
|Cranial imaging of an FFI patient. In the MRI, there are abnormal signals in the bilateral frontoparietal subcortical area. MRA showed smaller distal branches of cerebral arteries.|
|Specialty||Neurology, Psychiatry, Sleep medicine, Neuropathology|
|Symptoms||Progressive insomnia, ataxia, double vision, weight loss, high blood pressure, excessive sweating|
|Complications||Permanent state of hypnagogia later in the illness|
|Usual onset||45-50 years old |
|Types||Fatal familial insomnia, sporadic fatal insomnia|
|Causes||Genetic mutation, sporadic form (very rare)|
|Risk factors||Family history|
|Diagnostic method||Suspected based on symptoms, Supported by Sleep study, PET scan and genetic testing (If Familial form is suspected)|
|Differential diagnosis||Alzheimer's disease, frontotemporal dementia, other transmissible spongiform encephalopathies|
|Frequency||70 families worldwide are known to carry the gene associated with the disease, 37 sporadic cases diagnosed (as of September 20th, 2022)|
Signs and symptomsEdit
The disease has four stages:
- Characterized by worsening insomnia, resulting in panic attacks, paranoia, and phobias. This stage lasts for about four months.
- Hallucinations and panic attacks become noticeable, continuing for about five months.
- Complete inability to sleep is followed by rapid loss of weight. This lasts for about three months.
- Dementia, during which the person becomes unresponsive or mute over the course of six months, is the final stage of the disease, after which death follows.
Clinically, fatal insomnia manifests with a disordered sleep-wake cycle, dysautonomia, motor disturbances, and neuropsychiatric disorders.
Other symptoms include profuse sweating, miosis (pinpoint pupils), sudden entrance into menopause or impotence, neck stiffness, and elevation of blood pressure and heart rate. The sporadic form of the disease often presents with double vision. Constipation is common as well. As the disease progresses, the person becomes stuck in a state of pre-sleep limbo, or hypnagogia, which is the state just before sleep in healthy individuals. During these stages, people commonly and repeatedly move their limbs as if dreaming.
The prevalence of FFI is one case per a million population per year, with only about 57 cases in 27 kindreds have been reported worldwide.
The age of onset is variable, ranging from 13 to 60 years, with an average of 50. The disease can be detected prior to onset by genetic testing. Death usually occurs between 6–36 months from onset. The presentation of the disease varies considerably from person to person, even among people within the same family; in the sporadic form, for example, sleep problems are not commonly reported and early symptoms are ataxia, cognitive impairment, and double vision.
This rare hereditary prion disease is associated with the D178N-129M PRNP gene that is caused by a mutation. The gene PRNP that provides instructions for making the prion protein PrPC is located on the short (p) arm of chromosome 20 at position p13. Both people with FFI and those with familial Creutzfeldt–Jakob disease (fCJD) carry a mutation at codon 178 of the prion protein gene. FFI is also invariably linked to the presence of the methionine codon at position 129 of the mutant allele, whereas fCJD is linked to the presence of the valine codon at that position. "The disease is where there is a change of amino acid at position 178 when an asparagine (N) is found instead of the normal aspartic acid (D). This has to be accompanied with a methionine at position 129."
Fatal insomnia (FFI) is an autosomal dominant disease that harbors a missense GAC to AAC mutation at codon 178 of the PRNP prion protein gene located on chromosome 20, along with the presence of the methionine polymorphism at position 129 of the mutant allele. Pathologically, FFI is characterized by predominant thalamic degeneration especially in the medio-dorsal and anterio-ventral nuclei5, 6. Phenotypic variability is a perplexing feature of FFI.
Given its striking clinical and neuropathologic similarities with fatal familial insomnia (FFI), a genetic prion disease linked to a point mutation at codon 178 (D178N) in the PRNP coupled with methionine at codon 129, the MM2T subtype is also known as sporadic FI (sFI).6,7. Transmission studies using susceptible transgenic mice have consistently demonstrated that the same prion strain is associated with both sFI and FFI.8,9. In contrast to what has been the rule for the most common neurodegenerative disorders, sFI is rarer than its genetic counterpart.10 Whereas the recognized patients with FFI are numerous and belong to >50 families worldwide, only about 30 cases of CJD MM2T and a few cases with mixed MM2T and MM2C features (MM2T+C) have been recorded to date.
In itself, the presence of prions causes reduced glucose to use by the thalamus and a mild hypo-metabolism of the cingulate cortex. The extent of this symptom varies between two variations of the disease, these being those presenting methionine homozygotes at codon 129 and methionine/valine heterozygotes being the most severe in the latter one. Given the relationship between the involvement of the thalamus in regulating sleep and alertness, a causal relationship can be drawn, and is often mentioned as the cause.
Diagnosis is suspected based on symptoms and can be supported by a sleep study, a PET scan, and genetic testing if the patient's family has a history of the disease. Similar to other prion diseases, the diagnosis can only be confirmed by a brain autopsy at post-mortem. Further work up often include a sleep study and PET scan. Confirmation of the familial form is by genetic testing.
Other diseases involving the mammalian prion protein are known. Some are transmissible (TSEs, including FFI) such as kuru, bovine spongiform encephalopathy (BSE, also known as "mad cow disease") in cattle, and chronic wasting disease in American deer and American elk in some areas of the United States and Canada, as well as Creutzfeldt–Jakob disease (CJD). Until recently, prion diseases were only thought to be transmissible by direct contact with infected tissue, such as from eating infected tissue, transfusion, or transplantation; research suggests that prions can be transmitted by aerosols, but that the general public is not at risk of airborne infection.
Epidemiology & HistoryEdit
Fatal insomnia was first described by Lugaresi et al., in 1986.
In 1998, 40 families were known to carry the gene for FFI globally: eight German, five Italian, four American, two French, two Australian, two British, one Japanese, and one Austrian. In the Basque Country, Spain, 16 family cases of the 178N mutation were seen between 1993 and 2005 related to two families with a common ancestor in the 18th century. In 2011, another family was added to the list when researchers found the first man in the Netherlands with FFI. While he had lived in the Netherlands for 19 years, he was of Egyptian descent. Other prion diseases are similar to FFI and could be related, but are missing the D178N gene mutation.
As of 20 September 2022[update], 37 cases of sporadic fatal insomnia have been diagnosed. Unlike in FFI, those with sFI do not have the D178N mutation in the PRNP-prion gene; they all have a different mutation in the same gene causing methionine homozygosity at codon 129. Nonetheless, the methionine presence in lieu of the valine (Val129) is what causes the sporadic form of disease. The targeting of this mutation is another strategy that has been suggested as possible for treatment, or hopefully as cure for the disease.
Silvano, 1983, Bologna, ItalyEdit
In late 1983, Italian neurologist/sleep expert Dr. Ignazio Roiter received a patient at the University of Bologna hospital's sleep institute. The man, known only as Silvano, decided in a rare moment of consciousness to be recorded for future studies and to donate his brain for research in hopes of finding a cure for future victims.
Unnamed American patient, 2001Edit
In a 2006 published article, Schenkein and Montagna wrote of a 52-year-old American man who was able to exceed the average survival time by nearly one year with various strategies that included vitamin therapy and meditation, different stimulants and hypnotics, and even complete sensory deprivation in an attempt to induce sleep at night and increase alertness during the day. He managed to write a book and drive hundreds of miles in this time, but nonetheless, over the course of his trials, the man succumbed to the classic four-stage progression of the illness.
Egyptian man, 2011, NetherlandsEdit
In 2011, the first reported case in the Netherlands was of a 57-year-old man of Egyptian descent. The man came in with symptoms of double vision and progressive memory loss, and his family also noted he had recently become disoriented, paranoid, and confused. While he tended to fall asleep during random daily activities, he experienced vivid dreams and random muscular jerks during normal slow-wave sleep. After four months of these symptoms, he began to have convulsions in his hands, trunk, and lower limbs while awake. The person died at age 58, seven months after the onset of symptoms. An autopsy revealed mild atrophy of the frontal cortex and moderate atrophy of the thalamus. The latter is one of the most common signs of FFI.
Still with unclear benefit in humans, a number of treatments have had tentative success in slowing disease progression in animal models, including pentosan polysulfate, mepacrine, and amphotericin B. As of 2016[update], a study investigating doxycycline is being carried out.
In 2009, a mouse model was made for FFI. These mice expressed a humanized version of the PrP protein that also contains the D178N FFI mutation. These mice appear to have progressively fewer and shorter periods of uninterrupted sleep, damage in the thalamus, and early deaths, similar to humans with FFI.
The Prion Alliance was established by husband and wife duo Eric Minikel and Sonia Vallabh after Vallabh's mother was diagnosed with the fatal disease. They conduct research at the Broad Institute to develop therapeutics for human prion diseases. Other research interests involve identifying biomarkers to track the progression of prion disease in living people.
- "Fatal Familial Insomnia". NORD (National Organization for Rare Disorders). Retrieved 21 September 2022.
- "Fatal Insomnia – Neurologic Disorders". Merck Manuals Professional Edition. Retrieved 17 May 2019.
- "Fatal familial insomnia". Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. Retrieved 17 May 2019.
- "Fatal Familial Insomnia". NORD (National Organization for Rare Disorders). Retrieved 17 May 2019.
- "What is fatal familial insomnia?". Healthline. 26 January 2018. Retrieved 4 May 2018.
- "Fatal Insomnia". Merck Manual. Retrieved 4 May 2018.
- Turner, Rebecca. "Dying To Sleep: Fatal Familial Insomnia (FFI)". www.world-of-lucid-dreaming.com. Retrieved 22 March 2018.
- Cortelli, Pietro; Gambetti, Pierluigi; Montagna, Pasquale & Lugaresi, Elio (1999). "Fatal familial insomnia: clinical features and molecular genetics". Journal of Sleep Research. 8: 23–29. doi:10.1046/j.1365-2869.1999.00005.x. PMID 10389103. S2CID 24399165.
- "Episode 25: Fatal Insomnia". Obscura: A True Crime Podcast.
- Max, D.T. (May 2010). "The Secret of Sleep". National Geographic Magazine. p. 74.
- "Fatal Insomnia - Neurologic Disorders".
- Reference, Genetics Home h. "PRNP gene". Genetics Home Reference. Retrieved 22 March 2018.
- Khan, Z.; Bollu, P. C. (2021). "Fatal Familial Insomnia". Zalan Khan; Pradeep C. Bollu, Fatal Familial Insomnia. NCBI Bookshelf. StatPearls. PMID 29489284.
- Cortelli., P. (1 July 1997). "Cerebral metabolism in fatal familial insomnia: Relation to duration, neuropathology, and distribution of protease-resistant prion protein". Neurology. 49 (1): 126–33. doi:10.1212/WNL.49.1.126. PMID 9222180. S2CID 31614281. Retrieved 1 November 2019.
- "Sleep Spindle - an overview | ScienceDirect Topics".
- Panegyres, Peter; Burchell, Jennifer T. (2016). "Prion diseases: Immunotargets and therapy". ImmunoTargets and Therapy. 5: 57–68. doi:10.2147/ITT.S64795. ISSN 2253-1556. PMC 4970640. PMID 27529062.
- Mosher, Dave (13 January 2011). "Airborne prions make for 100 percent lethal whiff". Wired. Retrieved 20 May 2011.
- Turner, Rebecca. "The man who never slept: Michael Corke". World of Lucid Dreaming. Retrieved 20 May 2011.
- Schenkein, Joyce; Montagna, Pasquale (12 September 2006). "Self Management of Fatal Familial Insomnia. Part 1: What Is FFI?". Medscape General Medicine. 8 (3): 65. ISSN 1531-0132. PMC 1781306. PMID 17406188.
- Schenkein J, Montagna P (2006). "Self management of fatal familial insomnia. Part 1: what is FFI?". MedGenMed. 8 (3): 65. PMC 1781306. PMID 17406188.
- Montagna P, Gambetti P, Cortelli P, Lugaresi E (2003). "Familial and sporadic fatal insomnia". Lancet Neurol. 2 (3): 167–76. doi:10.1016/S1474-4422(03)00323-5. PMID 12849238. S2CID 20822956.
- Zarranz JJ, Arteagoitia JM, Atarés B, Rodríguez-Martínez AB, Martínez-de-Pancorbo M, et al. (2007). "Las encefalopatias espongiformes o enfermedades por priones en el País Vasco". GacMedBilbao. 104 (2): 64–69. doi:10.1016/S0304-4858(07)74572-9. PMID 10371520.
- Jansen, C.; Parchi, P.; Jelles, B.; Gouw, A. A.; Beunders, G.; van Spaendonk, R. M. L.; van de Kamp, J. M.; Lemstra, A. W.; Capellari, S.; Rozemuller, A. J. M. (13 July 2011). "The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent four repeat tau deposits". Neuropathology and Applied Neurobiology. 37 (5): 549–53. doi:10.1111/j.1365-2990.2010.01126.x. PMID 20874730. S2CID 30722366.
- Mehta LR, Huddleston BJ, Skalabrin EJ, et al. (July 2008). "Sporadic fatal insomnia masquerading as a paraneoplastic cerebellar syndrome". Arch. Neurol. 65 (7): 971–73. doi:10.1001/archneur.65.7.971. PMID 18625868.
- Moody KM, Schonberger LB, Maddox RA, Zou WQ, Cracco L, Cali I (2011). "Sporadic fatal insomnia in a young woman: A diagnostic challenge". Case report. BMC Neurol. 11: 136. doi:10.1186/1471-2377-11-136. PMC 3214133. PMID 22040318.
- Tabaee Damavandi P, Dove MT, Pickersgill RW, et al. (August 2017). "A review of drug therapy for sporadic fatal insomnia". Prion. 11 (5): 293–99. doi:10.1080/19336896.2017.1368937. PMC 5639864. PMID 28976233.
- Schenkein J, Montagna P (2006). "Part 2: Case report". MedGenMed: Medscape General Medicine. Self-management of fatal familial insomnia. 8 (3): 66. PMC 1781276. PMID 17406189.
- Forlonia, Gianluigi; Tettamantia, Mauro; Luccaa, Ugo; Albanesea, Yasmin; Quaglioa, Elena; Chiesaa, Roberto; Erbettab, Alessandra; Villanib, Flavio; Redaellib, Veronica; Tagliavinib, Fabrizio; Artusoc, Vladimiro; Roiterc, Ignazio (21 May 2015). "Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases". Prion. 9 (2): 75–79. doi:10.1080/19336896.2015.1027857. PMC 4601344. PMID 25996399.
- Jackson W, et al. (2009). "Spontaneous beneration of prion infectivity in fatal familial insomnia Knockin mice". Neuron. 63 (4): 438–50. doi:10.1016/j.neuron.2009.07.026. PMC 2775465. PMID 19709627.
- Clancy, Kelly (15 January 2019). "One Couple's Tireless Crusade to Stop a Genetic Killer". Wired. ISSN 1059-1028. Retrieved 21 January 2019.
- "Sonia Vallabh". Broad Institute. 20 August 2015. Retrieved 21 January 2019.
- "Prion Alliance". www.prionalliance.org. Retrieved 21 January 2019.